**Author details**

Bridget M. Deasy1,2\*, Jordan E. Anderson3 and Shannon Zelina1

\*Address all correspondence to: deasybm@gmail.com

1 CellStock, Pittsburgh, PA, USA

2 McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, USA

3 Dept. of Biomedical Engineering, School of Engineering, University of Connecticut, Storrs, CT, USA

### **References**


[7] *US Food and Drug Administration. Guidance for Industry. Current Good Tissue Practice (CGTP) and Additional Requirements for Manufacturers of Human Cells, Tissues, and Cel‐ lular and Tissue-Based Products (HCT/Ps).* 2011.

pose risk to patients and the careful development of the field. The current challenge to deliv‐ er safe cell and tissue therapies and curb unregulated treatments may soon apply to gene therapy and other innovative technologies. Early government regulation and active educa‐ tion by a number of professional organizations should reduce the spread of medical tourism and aid in the development of safe and effective treatments in the field of regenerative med‐

and Shannon Zelina1

2 McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA,

3 Dept. of Biomedical Engineering, School of Engineering, University of Connecticut, Storrs,

[1] ISSCR, *Guidelines for the Clinical Translation of Stem Cells.* International Society for

[2] Amariglio, N., et al., *Donor-derived brain tumor following neural stem cell transplantation*

[3] Liang, B.A. and T. Mackey, *Confronting conflict: addressing institutional conflicts of inter‐*

[4] Wilson, R.F., *The death of Jesse Gelsinger: new evidence of the influence of money and pres‐*

[5] Lau, D., et al., *Stem cell clinics online: the direct-to-consumer portrayal of stem cell medi‐*

[6] National Academies (U.S.). Committee on Ranking FDA Product Categories Based on Health Consequences Phase II. and National Research Council (U.S.), *A risk-char‐ acterization framework for decision-making at the Food and Drug Administration*. 2011,

*in an ataxia telangiectasia patient.* PLoS Med, 2009. 6(2): p. e1000029.

*est in academic medical centers.* Am J Law Med, 2010. 36(1): p. 136-87.

*tige in human research.* Am J Law Med, 2010. 36(2-3): p. 295-325.

Washington, D.C.: National Academies Press. xiv, 192 p.

icine.

USA

CT, USA

**References**

**Author details**

Bridget M. Deasy1,2\*, Jordan E. Anderson3

Stem Cell Research, 2008.

*cine.* Cell Stem Cell, 2008. 3(6): p. 591-4.

1 CellStock, Pittsburgh, PA, USA

212 Regenerative Medicine and Tissue Engineering

\*Address all correspondence to: deasybm@gmail.com


[38] Kim, J.B., et al., *Pluripotent stem cells induced from adult neural stem cells by reprogram‐ ming with two factors.* Nature, 2008. 454(7204): p. 646-50.

[22] Han, J. and K.S. Sidhu, *Current concepts in reprogramming somatic cells to pluripotent*

[23] Do, J.T., D.W. Han, and H.R. Scholer, *Reprogramming somatic gene activity by fusion*

[24] Zeng, X. and M.S. Rao, *Human embryonic stem cells: long term stability, absence of senes‐ cence and a potential cell source for neural replacement.* Neuroscience, 2007. 145(4): p.

[25] Atkinson, S. and L. Armstrong, *Epigenetics in embryonic stem cells: regulation of pluripo‐*

[26] Tavakoli, T., et al., *Self-renewal and differentiation capabilities are variable between human*

[27] Bhattacharya, B., S. Puri, and R.K. Puri, *A review of gene expression profiling of human embryonic stem cell lines and their differentiated progeny.* Curr Stem Cell Res Ther, 2009.

[28] Guenther, M.G., et al., *Chromatin structure and gene expression programs of human em‐ bryonic and induced pluripotent stem cells.* Cell Stem Cell, 2010. 7(2): p. 249-57.

[29] Yu, J., et al., *Induced pluripotent stem cell lines derived from human somatic cells.* Science,

[30] Shafa, M., R. Krawetz, and D.E. Rancourt, *Returning to the stem state: epigenetics of re‐ capitulating pre-differentiation chromatin structure.* Bioessays, 2010. 32(9): p. 791-9.

[31] Newman, A.M. and J.B. Cooper, *Lab-specific gene expression signatures in pluripotent*

[32] Hong, S.H., et al., *Cell fate potential of human pluripotent stem cells is encoded by histone*

[33] Scott, C.T., et al., *Democracy Derived? New Trajectories in Pluripotent Stem Cell Research.*

[34] Lee, H., et al., *Induced pluripotent stem cells in regenerative medicine: an argument for con‐ tinued research on human embryonic stem cells.* Regen Med, 2009. 4(5): p. 759-69.

[35] Zavazava, N., *Immunity of embryonic stem cell-derived hematopoietic progenitor cells.*

[36] Broxmeyer, H.E., *Will iPS cells enhance therapeutic applicability of cord blood cells and*

[37] Taylor, C.J., E.M. Bolton, and J.A. Bradley, *Immunological considerations for embryonic and induced pluripotent stem cell banking.* Philos Trans R Soc Lond B Biol Sci, 2011.

*embryonic stem cell lines I3, I6 and BG01V.* BMC Cell Biol, 2009. 10: p. 44.

*state.* Curr Stem Cell Res Ther, 2008. 3(1): p. 66-74.

1348-58.

214 Regenerative Medicine and Tissue Engineering

4(2): p. 98-106.

2007. 318(5858): p. 1917-20.

Cell, 2011. 145(6): p. 820-6.

Semin Immunopathol, 2011.

366(1575): p. 2312-22.

*banking?* Cell Stem Cell, 2010. 6(1): p. 21-4.

*stem cells.* Cell Stem Cell, 2010. 7(2): p. 258-62.

*modifications.* Cell Stem Cell, 2011. 9(1): p. 24-36.

*with pluripotent cells.* Stem Cell Rev, 2006. 2(4): p. 257-64.

*tency and differentiation.* Cell Tissue Res, 2008. 331(1): p. 23-9.


[71] Yang, S., et al., *Tumor progression of culture-adapted human embryonic stem cells during long-term culture.* Genes Chromosomes Cancer, 2008. 47(8): p. 665-79.

[54] Murohara, T., *Autologous adipose tissue as a new source of progenitor cells for therapeutic*

[55] He, X., et al., *[Morphological characteristics of human adipose-derived stem cells].* Sheng

[56] Bobbert, M., *Ethical questions concerning research on human embryos, embryonic stem cells*

[57] Hug, K., *Sources of human embryos for stem cell research: ethical problems and their possible*

[58] Hug, K. and G. Hermeren, *Do we Still Need Human Embryonic Stem Cells for Stem Cell-*

[59] Knoepfler, P.S., *Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative*

[60] Zacharias, D.G., et al., *The science and ethics of induced pluripotency: what will become of*

[61] Volarevic, V., et al., *Human stem cell research and regenerative medicine--present and fu‐*

[62] Lowry, W.E. and W.L. Quan, *Roadblocks en route to the clinical application of induced*

[63] Walia, B., et al., *Induced Pluripotent Stem Cells: Fundamentals and Applications of the Re‐ programming Process and its Ramifications on Regenerative Medicine.* Stem Cell Rev,

[64] Kiefer, J.C., *Primer and interviews: Promises and realities of induced pluripotent stem cells.*

[65] Zhou, H. and S. Ding, *Evolution of induced pluripotent stem cell technology.* Curr Opin

[66] Amabile, G. and A. Meissner, *Induced pluripotent stem cells: current progress and poten‐*

[67] Deng, W., *Exploiting pluripotency for therapeutic gain.* Panminerva Med, 2010. 52(2): p.

[68] Baker, D.E., et al., *Adaptation to culture of human embryonic stem cells and oncogenesis in*

[69] Blum, B. and N. Benvenisty, *The tumorigenicity of human embryonic stem cells.* Adv

[70] Enver, T., et al., *Cellular differentiation hierarchies in normal and culture-adapted human*

*tial for regenerative medicine.* Trends Mol Med, 2009. 15(2): p. 59-68.

*embryonic stem cells.* Hum Mol Genet, 2005. 14(21): p. 3129-40.

*angiogenesis.* J Cardiol, 2009. 53(2): p. 155-63.

216 Regenerative Medicine and Tissue Engineering

*and chimeras.* Biotechnol J, 2006. 1(12): p. 1352-69.

*medicine.* Stem Cells, 2009. 27(5): p. 1050-6.

*ture.* Br Med Bull, 2011.

Dev Dyn, 2011. 240(8): p. 2034-41.

Hematol, 2010. 17(4): p. 276-80.

*vivo.* Nat Biotechnol, 2007. 25(2): p. 207-15.

Cancer Res, 2008. 100: p. 133-58.

2011.

167-73.

*solutions.* Medicina (Kaunas), 2005. 41(12): p. 1002-10.

*Based Therapies? Epistemic and Ethical Aspects.* Stem Cell Rev, 2011.

*embryonic stem cells?* Mayo Clin Proc, 2011. 86(7): p. 634-40.

*pluripotent stem cells.* J Cell Sci, 2010. 123(Pt 5): p. 643-51.

Wu Yi Xue Gong Cheng Xue Za Zhi, 2011. 28(2): p. 337-41.

